%0 Journal Article
%A Sun, Zhaowei
%A Wang, Lei
%A Wu, Shuai
%A Pan, Yanhong
%A Dong, Yu
%A Zhu, Sha
%A Yang, Jie
%A Yin, Yongmei
%A Li, Genxi
%D 2020
%T An Electrochemical Biosensor Designed by Using Zr-Based
Metal–Organic Frameworks for the Detection of Glioblastoma-Derived
Exosomes with Practical Application
%U https://acs.figshare.com/articles/journal_contribution/An_Electrochemical_Biosensor_Designed_by_Using_Zr-Based_Metal_Organic_Frameworks_for_the_Detection_of_Glioblastoma-Derived_Exosomes_with_Practical_Application/11857968
%R 10.1021/acs.analchem.9b05241.s001
%2 https://acs.figshare.com/ndownloader/files/21732936
%K GBM-derived exosomes
%K Practical Application Glioblastoma
%K epidermal growth factor receptor
%K MOF
%K BBB
%K EGFR
%K III
%K diagnosis
%K label-free electrochemical biosensor
%X Glioblastoma
(GBM) is one of the most fatal tumors in the brain,
and its early diagnosis remains technically challenging due to the
complex repertoires of oncogenic alterations and blood-brain barrier
(BBB). GBM-derived specific exosomes can cross the BBB and circulate
in body fluids, so they can be noninvasive biomarkers for the early
diagnosis of GBM. Herein, we propose a sensitive and label-free electrochemical
biosensor designed by using Zr-based metal–organic frameworks
(Zr-MOFs) for the detection of GBM-derived exosomes with practical
application. In the design, a peptide ligand can specifically bind
with human epidermal growth factor receptor (EGFR) and EGFR variant
(v) III mutation (EGFRvIII), which are overexpressed on the GBM-derived
exosomes. Meanwhile, Zr-MOFs encapsulated with methylene blue can
absorb on the surface of the exosomes due to the interaction between
Zr4+ and the intrinsic phosphate groups outside of exosomes.
Consequently, the concentration of exosomes can be directly quantified
by monitoring the electroactive molecules inside MOFs, ranging from
9.5 × 103 to 1.9 × 107 particles/μL
with the detection of limit of 7.83 × 103 particles/μL.
Furthermore, this proposed biosensor can distinguish GBM patients
from healthy groups, demonstrating the great prospect for early clinical
diagnosis.
%I ACS Publications